Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Rescue of protein expression defects may not be enough to abolish the pro-arrhythmic phenotype of long QT type 2 mutations.
Perry MD, Ng CA, Phan K, David E, Steer K, Hunter MJ, Mann SA, Imtiaz M, Hill AP, Ke Y, Vandenberg JI.
???displayArticle.abstract???
KEY POINTS: Most missense long QT syndrome type 2 (LQTS2) mutations result in Kv11.1 channels that show reduced levels of membrane expression. Pharmacological chaperones that rescue mutant channel expression could have therapeutic potential to reduce the risk of LQTS2-associated arrhythmias and sudden cardiac death, but only if the mutant Kv11.1 channels function normally (i.e. like WT channels) after membrane expression is restored. Fewer than half of mutant channels exhibit relatively normal function after rescue by low temperature. The remaining rescued missense mutant Kv11.1 channels have perturbed gating and/or ion selectivity characteristics. Co-expression of WT subunits with gating defective missense mutations ameliorates but does not eliminate the functional abnormalities observed for most mutant channels. For patients with mutations that affect gating in addition to expression, it may be necessary to use a combination therapy to restore both normal function and normal expression of the channel protein.
ABSTRACT: In the heart, Kv11.1 channels pass the rapid delayed rectifier current (IKr ) which plays critical roles in repolarization of the cardiac action potential and in the suppression of arrhythmias caused by premature stimuli. Over 500 inherited mutations in Kv11.1 are known to cause long QT syndrome type 2 (LQTS2), a cardiac electrical disorder associated with an increased risk of life threatening arrhythmias. Most missense mutations in Kv11.1 reduce the amount of channel protein expressed at the membrane and, as a consequence, there has been considerable interest in developing pharmacological agents to rescue the expression of these channels. However, pharmacological chaperones will only have clinical utility if the mutant Kv11.1 channels function normally after membrane expression is restored. The aim of this study was to characterize the gating phenotype for a subset of LQTS2 mutations to assess what proportion of mutations may be suitable for rescue. As an initial screen we used reduced temperature to rescue expression defects of mutant channels expressed in Xenopus laevis oocytes. Over half (∼56%) of Kv11.1 mutants exhibited functional gating defects that either dramatically reduced the amount of current contributing to cardiac action potential repolarization and/or reduced the amount of protective current elicited in response to premature depolarizations. Our data demonstrate that if pharmacological rescue of protein expression defects is going to have clinical utility in the treatment of LQTS2 then it will be important to assess the gating phenotype of LQTS2 mutations before attempting rescue.
Anderson,
Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism.
2006, Pubmed
Anderson,
Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism.
2006,
Pubmed Anderson,
Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome.
2014,
Pubmed Balijepalli,
Rescue of mutated cardiac ion channels in inherited arrhythmia syndromes.
2010,
Pubmed Balijepalli,
Mechanism of loss of Kv11.1 K+ current in mutant T421M-Kv11.1-expressing rat ventricular myocytes: interaction of trafficking and gating.
2012,
Pubmed Bellin,
Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome.
2013,
Pubmed Berecki,
HERG channel (dys)function revealed by dynamic action potential clamp technique.
2005,
Pubmed Bezzina,
Genetics of sudden cardiac death.
2015,
Pubmed Collins,
A new initiative on precision medicine.
2015,
Pubmed Conn,
Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.
2014,
Pubmed Conn,
Assay strategies for identification of therapeutic leads that target protein trafficking.
2015,
Pubmed Curran,
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.
1995,
Pubmed Delisle,
Biology of cardiac arrhythmias: ion channel protein trafficking.
2004,
Pubmed Fedida,
hERG long QT syndrome type 2 mutants need more than a chaperone to dance.
2017,
Pubmed Gerlach,
Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574).
2010,
Pubmed Gianulis,
Rescue of aberrant gating by a genetically encoded PAS (Per-Arnt-Sim) domain in several long QT syndrome mutant human ether-á-go-go-related gene potassium channels.
2011,
Pubmed Gianulis,
Direct interaction of eag domains and cyclic nucleotide-binding homology domains regulate deactivation gating in hERG channels.
2013,
Pubmed Gomes,
Protein misfolding in disease and small molecule therapies.
2012,
Pubmed Gong,
Degradation of trafficking-defective long QT syndrome type II mutant channels by the ubiquitin-proteasome pathway.
2005,
Pubmed Gong,
Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long-QT syndrome.
2007,
Pubmed Gustina,
hERG potassium channel gating is mediated by N- and C-terminal region interactions.
2011,
Pubmed
,
Xenbase Janovick,
Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy.
2013,
Pubmed Jou,
An in vivo cardiac assay to determine the functional consequences of putative long QT syndrome mutations.
2013,
Pubmed Ju,
The pore domain outer helix contributes to both activation and inactivation of the HERG K+ channel.
2009,
Pubmed Kagan,
The dominant negative LQT2 mutation A561V reduces wild-type HERG expression.
2000,
Pubmed Kang,
Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
2005,
Pubmed Kanters,
Combined gating and trafficking defect in Kv11.1 manifests as a malignant long QT syndrome phenotype in a large Danish p.F29L founder family.
2015,
Pubmed Ke,
Role of the cytoplasmic N-terminal Cap and Per-Arnt-Sim (PAS) domain in trafficking and stabilization of Kv11.1 channels.
2014,
Pubmed Ke,
Trafficking defects in PAS domain mutant Kv11.1 channels: roles of reduced domain stability and altered domain-domain interactions.
2013,
Pubmed
,
Xenbase Leidenheimer,
Pharmacological chaperoning: a primer on mechanism and pharmacology.
2014,
Pubmed Liu,
Eag Domains Regulate LQT Mutant hERG Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
2015,
Pubmed
,
Xenbase Lu,
Effects of premature stimulation on HERG K(+) channels.
2001,
Pubmed Matsa,
Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes.
2014,
Pubmed Mehta,
Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.
2014,
Pubmed Moss,
25th anniversary of the International Long-QT Syndrome Registry: an ongoing quest to uncover the secrets of long-QT syndrome.
2005,
Pubmed Moss,
Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel.
2002,
Pubmed Muskett,
Mechanistic insight into human ether-à-go-go-related gene (hERG) K+ channel deactivation gating from the solution structure of the EAG domain.
2011,
Pubmed Nerbonne,
Molecular physiology of cardiac repolarization.
2005,
Pubmed Ng,
Multiple interactions between cytoplasmic domains regulate slow deactivation of Kv11.1 channels.
2014,
Pubmed
,
Xenbase Ng,
The S4-S5 linker acts as a signal integrator for HERG K+ channel activation and deactivation gating.
2012,
Pubmed Perry,
Revealing the structural basis of action of hERG potassium channel activators and blockers.
2010,
Pubmed Perry,
Pore helices play a dynamic role as integrators of domain motion during Kv11.1 channel inactivation gating.
2013,
Pubmed
,
Xenbase Riordan,
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.
1989,
Pubmed Sadrieh,
Multiscale cardiac modelling reveals the origins of notched T waves in long QT syndrome type 2.
2014,
Pubmed Sanguinetti,
Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.
1990,
Pubmed Sanguinetti,
Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia.
1996,
Pubmed
,
Xenbase Sanguinetti,
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
1995,
Pubmed
,
Xenbase Shimizu,
Genotype-phenotype aspects of type 2 long QT syndrome.
2009,
Pubmed Smith,
The inward rectification mechanism of the HERG cardiac potassium channel.
1996,
Pubmed Solomon,
Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
2015,
Pubmed Sosnay,
Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene.
2013,
Pubmed Spector,
Fast inactivation causes rectification of the IKr channel.
1996,
Pubmed
,
Xenbase Splawski,
Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2.
2000,
Pubmed Thomson,
Concerted all-or-none subunit interactions mediate slow deactivation of human ether-à-go-go-related gene K+ channels.
2014,
Pubmed
,
Xenbase Vandenberg,
hERG K(+) channels: structure, function, and clinical significance.
2012,
Pubmed Viskin,
The QT interval: too long, too short or just right.
2009,
Pubmed Wang,
Mapping the sequence of conformational changes underlying selectivity filter gating in the K(v)11.1 potassium channel.
2011,
Pubmed Wu,
Cooperative subunit interactions mediate fast C-type inactivation of hERG1 K+ channels.
2014,
Pubmed
,
Xenbase Wynia-Smith,
hERG gating microdomains defined by S6 mutagenesis and molecular modeling.
2008,
Pubmed Zarraga,
Nonsense-mediated mRNA decay caused by a frameshift mutation in a large kindred of type 2 long QT syndrome.
2011,
Pubmed Zemzemi,
Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials.
2013,
Pubmed Zeng,
Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.
2006,
Pubmed Zhang,
LQTS gene LOVD database.
2010,
Pubmed Zhang,
Translational toxicology and rescue strategies of the hERG channel dysfunction: biochemical and molecular mechanistic aspects.
2014,
Pubmed Zhao,
Not all hERG pore domain mutations have a severe phenotype: G584S has an inactivation gating defect with mild phenotype compared to G572S, which has a dominant negative trafficking defect and a severe phenotype.
2009,
Pubmed Zhou,
Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects.
1999,
Pubmed